Participate in
Research at
CU Anschutz

Participate in
Research at
CU Anschutz

Participate in
Research at
CU Anschutz

Participate in
Research at
CU Anschutz

Participate in
Research at
CU Anschutz

I'm Interested

Study: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)
Please select your preferred method of contact

Thank you for expressing your interest in a research study and for taking the time to provide your information.

By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 3 to 5 business days.

Please understand that:

  • The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
  • It is always your choice to participate.

Thanks again. Volunteers such as yourself are at the core of our work.